Testing effectiveness (Phase 2)Study completedNCT03543813
What this trial is testing
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
Who this might be right for
Solid Tumor, AdultHead and Neck CancerNon Small Cell Lung Cancer+2 more
CytomX Therapeutics 133